Leadership

Walter (Wally) Reiher, Ph.D.

Chief Information Officer

Wally has spent the last 35 years leveraging technology to deliver insights, foster collaboration, enhance business processes and improve efficiency. He played a key role in the early development of a number of molecular modeling software companies and did research in computational chemistry as an independent contractor at Sterling Winthrop, Eastman Kodak, and Sanofi.

Seeking a broader impact on research, Wally moved into research informatics, leading the implementation of decision support systems for drug discovery at Chiron, Affymax and Exelixis. Most recently, he held the position of vice president of information technology (IT) at Exelixis, where he delivered a number of major infrastructure projects, including the successful reimplementation of the company’s SAP ERP system.

Wally earned his Ph.D. in computational chemistry from Harvard University in the laboratory of Martin Karplus, 2013 Nobel Laureate in Chemistry. He holds a bachelor’s degree in chemistry from the University of California, San Diego.

Shaoling Li, Ph.D.

Senior Vice President, CMC & Quality

Throughout her career, Shaoling has been passionate about developing novel therapeutics to make a difference in patient’s lives.   Shaoling started her career as a formulation scientist focusing on novel drug delivery technology and product development.  With over 20 years of experience and a proven track record of developing drug products from early feasibility to clinical development and commercialization, Shaoling brings rich experience and expertise in various CMC functions including analytical development, pharmaceutical science and drug delivery, process development and manufacturing, cGMP compliance, and regulatory submission.

Prior to joining RevMed, Shaoling worked at various pharmaceutical and biotech companies including ALZA, J&J, Nanopax and Theravance.   She made significant contributions to the design and development of the transdermal product (Duragesic^®) led to commercialization.   Shaoling is the author or co-author on more than 20 scientific publications and a named inventor on several patents and applications.

Shaoling received her BS degree in Pharmacy and MS degree in Pharmaceutics from China Pharmaceutical University in China, and Ph.D. in Pharmaceutics from the University of Iowa.

Bojena Bitman, M.Sc.

Vice President, Quantitative Sciences

Raised in the family of mathematicians and engineers, Bojena was destined to join the analytical field. A desire to apply her technical abilities to making a difference in patient lives brought her to the unique department of Medical Cybernetics while in Medical School in Russia. In this department, medical science and analytics went hand to hand. This Medical Cybernetics experience guided Bojena to receive her BS degree in Microbiology from UCSB and MS degree in Biostatistics from UCLA. Bojena now has over 20 years of experience working in the pharmaceutical and biotech industry and is passionate about developing novel therapies for patients.
 
Bojena joined Revolution Medicines in 2019 and heads Quantitative Sciences comprised of Biostatistics and Translational Medicine groups where she applies her broad knowledge in clinical, biological, and statistical fields.

Previously Bojena has made substantial contributions to the clinical development and approval of BTK inhibitor CALQUENCE (Acalabrutinib) at Acerta Pharma (a subsidiary of AstraZeneca), has served in the role of global statistical lead for ENBREL (etanercept) at Amgen, and supported clinical and statistical teams working on developing vaccines and biologics at Vaxgen and Baxter.

Stephen Chan, B.Sc.

Vice President, Clinical Data Management, Statistical Programming, & Clinical Systems

Stephen has a passion for building efficient data infrastructure for delivering more real-time insights to inform strategic decisions, enhance collaboration, and accelerate advancements that could benefit public health. Stephen’s 25+ years of experience spans multiple therapeutic areas including oncology, infectious diseases, cardiovascular disorders, and CNS.  Since joining Revolution Medicines in 2018, he has built a formidable team comprised of the Statistical Programming, Clinical Data Management, and Clinical Systems functions.

Stephen began his oncology journey at the Lawrence Berkeley National Laboratory studying the effects of various growth factors on the branching of epithelial cells in relation to mammary carcinogenesis. From there his biotech and pharmaceutical career advanced with his previous role being Senior Director and Head of Statistical Programming for Acerta Pharma (AstraZeneca subsidiary) where he built and led the programming team to support multiple hematology and solid tumor studies toward the regulatory submission and approval of CALQUENCE® (acalabrutinib). Prior to Acerta Pharma, he played a key role in Pharmacyclics’ initial NDA submission and approval of IMBRUVICA® (ibrutinib). He was also a key contributor to the BEXXAR® (iodine-131 tositumomab) and FluMist® (live attenuated influenza vaccine, intranasal) regulatory submissions and approvals.

Stephen earned his Bachelor’s in Integrative Biology from the University of California at Berkeley.

Tamara Kale, Ph.D., J.D.

Vice President, Intellectual Property

Tamara’s scientific journey began with excellent and engaging chemistry teachers in high school and college, leading her to graduate school at the University of Minnesota. During an internship at 3M the summer before classes began, she learned about patent law as a career. With this option and the eventual decision to move away from the lab, the prospect of patent law allowed her to use her organic chemistry training, appreciation of writing, and practical problem-solving skills in pursuit of patient benefit and led her next to law school where she graduated from the University of Washington School of Law.

As an Associate in various law firms, Tamara encountered a wide variety of chemistry-related inventions, but always gravitated toward pharmaceutical discoveries. Moving in-house allowed her to focus on therapeutics and work with drug hunters bringing medicines to market. At Genentech, she gained valuable legal experience in a dynamic environment on a global scale where she was the Small Molecule IP Lead in the legal department for several years.

Tamara was drawn to join RevMed in the spring of 2019 in part because her graduate work was in the field of RAS proteins. She enjoys collaborating with business leaders and scientists as she helps preserve the value of the company’s IP assets, from research and development towards commercialization. She is a member of the Texas and California bars and is a registered patent attorney with the U.S. Patent & Trademark Office.

Elena Koltun, Ph.D.

Vice President, Medicinal Chemistry

Elena is an experienced Medicinal Chemist and a leader with an impressive delivery track record across a variety of therapeutic areas, including oncology. With 20 years of experience in the biotech industry, Elena is passionate about small molecule drug discovery and early development. Having worked previously at Exelixis and Numerate, she has taken many programs from concept stage to first in human. Elena is a co-inventor of Cotellic® (Cobimetinib), a MEK inhibitor developed by Exelixis and marketed by Genentech.

Elena joined Revolution Medicines in 2015 and has made significant contributions to the company’s pipeline and development of its unique tri-complex platform. She led chemistry efforts for the RAS Companion Inhibitor RMC-4630, led the team that advanced the RAS(ON) Inhibitor RMC-6236 into development, and made pivotal contributions to the discovery of the clinical candidates RMC-6291 and RMC-5845.

Elena received her Ph.D. in organic chemistry from the University of Minnesota and completed postdoctoral training at the University of Illinois at Chicago. Elena has authored multiple scientific publications and is a co-inventor on over 25 issued patents and applications.

Jason Lindow, B.Sc.

Vice President, Clinical Operations

Jason is driven to execute clinical programs in his 25 years of experience spanning multiple indications with a focus on hematology and oncology. He planned, initiated, and managed dozens of complex, first-in-human and late staged oncology programs. He has a track record of accelerating timelines while maintaining good clinical practice. His experience in large and small biotechnology companies, as well as CROs, formed a wide foundation of clinical development experience.

Jason started his career at ALZA Corporation studying the effects of hormone replacement therapy in AIDS patients. He went on to work at Parexel and Clinimetrics conducting trials in HIV, renal cell carcinoma, and pain management. His focus in oncology started during his time at Genentech where he executed humanized monoclonal antibody treatments for various cancers. At Gilead, he drove the burgeoning oncology pipeline with a focus on first-in-human solid tumor drug development, and at AbbVie, he executed over 20 first-in-human trials with immunology-oncology products both as single agent and in novel-novel combinations to clinical proof of concept.  

Since joining RevMed in 2021, Jason leads the growing Clinical Operations department. He graduated from UC San Diego and has held positions of increasing responsibility throughout his career.   

Robert Nichols, Ph.D.

Vice President, Corporate Development

A lifelong Chicago Cubs fan, Bob was raised with a sense of optimism and commitment that he’d later realize is perfectly matched to the pursuit of scientific discovery and innovation. After over a decade in basic science, Bob found drug discovery, and his beloved Cubs finally found their World Series trophy.

Bob has almost ten years of industry experience and is an original member of the RevMed team.  A systems biologist by training, he spent six years in R&D before transitioning to the science/business interface, supporting corporate development and partnering, investor relations, and financing activities.

Bob joined Revolution Medicines at the founding of the company and has made significant contributions to the company’s pipeline, particularly development of its unique RAS(ON) inhibitor portfolio. He served as project team lead for the RMC-4630, RMC-6291 and RMC-8839 project teams, guiding all three through development candidate nominations and into preclinical development. On the corporate side, Bob has been an integral part of all aspects of partnering including scientific presentation, diligence, commercial assessment, modeling, and negotiations.

Bob received his Ph.D. in systems biology from the University of California at San Francisco, completed an EMBO training fellowship at the Centre for Genomic Regulation in Barcelona, and a postdoctoral training fellowship at Stanford University.

Mallika Singh, Ph.D.

Vice President, Translational Research

Mallika has almost 20 years of industry research and drug development experience across the spectrum of current oncology therapeutics. She is an acknowledged scientific and strategic thought leader in translational research and in the use of sophisticated mouse models of human cancer for oncology drug development. Her research endeavors have driven insights into determinants of therapeutic response to MAP kinase pathway inhibition in RAS and RAF mutant cancers. She has established and led scientific programs in small biotechnology as well as biopharmaceutical companies including Genentech and Novartis.  Mallika has contributed to multiple investigational new drug applications including for vismodegib (Genentech/Roche) and the clinical-stage RAF inhibitor LXH254 (Novartis).

Since joining RevMed in 2017, Mallika has overseen the establishment of a world-class Cancer Pharmacology function which has had significant impact on all pipeline programs, including comprehensive pharmacology approaches and preclinical to clinical translation of our advancing pipeline. The Translational Research group she leads is also responsible for research diagnostics and combination strategies, all focused on driving RevMed’s pipeline assets towards clinical success and ultimately, patient benefit.

Mallika received a Ph.D. from the University of Utah and postdoctoral training at the University of California at San Francisco.  She is a co-author on numerous publications and a named inventor on several patents and applications.

Marieke van den Haak, Ph.D.

Vice President, Program, Portfolio and Alliance Management

Marieke is a strategic leader with over 20 years of experience working in the biopharmaceutical industry, where she has applied her scientific curiosity, analytical mindset, and strategic thinking to a broad range of disciplines including decision analysis, alliance management, portfolio management, insight generation, program management, and commercial and financial evaluations.

Previously, Marieke worked at Theravance Biopharma and GSK, where she has held a variety of roles of increasing responsibilities across research, development, and commercial functions. Marieke has a strong record in the international environment and has worked in the UK and Ireland before moving to the Bay Area in California. She is a skilled leader with experience in growing teams and building positive, collaborative partner relationships.

Marieke holds a Master of Science in Biopharmaceutical Sciences from the Leiden/ Amsterdam Centre for Drug Research (LACDR), Leiden University in The Netherlands and received a PhD from the School of Pharmacy, University of Wales (Cardiff, UK) for her study on the efficiency and productivity of the pharmaceutical industry.

Zhengping Wang, Ph.D.

Vice President, Non-clinical Development and Clinical Pharmacology

Starting her career as a research scientist, Zhengping has always been fascinated by breakthroughs in basic research that lead to improved understanding, preventing, diagnosing, and treatment of many diseases. She is dedicated to helping patients by bringing scientific discoveries from “Bench to Bedside”. 

During her 17 years in biotechnology industry, she has worked on drug discovery and development projects in all phases across a range of therapeutic areas, including oncology/hematology, cardiovascular and autoimmune diseases.

Previously, Zhengping worked at Amgen and Onyx Pharmaceutics, a subsidiary of Amgen. She acted as the interim head of research during the integration of Onyx into Amgen’s global organization. Zhengping was a key contributor to the nonclinical development, clinical pharmacology, and global approval of proteosome inhibitor Kyprolis® (carfilzomib) in multiple myeloma. She also made significant contributions to the discovery and development of oral proteasome inhibitor oprozomib. Prior to Onyx, she worked for Proteolix and Cytokinetics.

Zhengping received her Ph.D. In Chemistry from the University of Alberta, Canada. She holds a Bachelor of Science in Chemistry and a Master of Science in Analytical Chemistry from Wuhan University in China.

Pete Wildes, Ph.D.

Vice President, Cancer Biology

Pete is enthusiastic about applying rigorous, collaborative scientific inquiry to enable successful drug discovery and development. He has a multidisciplinary background in biochemistry, protein engineering, and chemical biology, and broad experience in the biotech industry, having previously worked in protein engineering for the industrial biotech sector, as head of the Biochemistry department at Dupont Industrial Biosciences.  

Pete joined Revolution Medicines in 2015 and has been a major contributor to the pipeline, including developing screening programs to support discovery of RMC-4630 and RMC-5552, and leading an integrated, multidisciplinary approach incorporating chemical biology, biochemistry, and cell biology to support discovery and development of the tri-complex RAS inhibitor programs. He built a world-class in vitro biology program that has been key to understanding the unique mechanisms of the tri-complex RAS inhibitor platform, and the intricacies of RAS biology that underly the right choice of RAS inhibitors and companions for translation to the clinic.   

Pete graduated from Cornell University with a BA in Biology and received his Ph.D. in Molecular and Cell Biology from UC Berkeley working in the laboratory of Susan Marqusee. He also conducted postdoctoral research with Jim Wells at UCSF. Pete is a co-author/inventor on multiple scientific publications and patent applications.   

Linnet Zia, B.A.

Vice President, Financial Planning & Analysis and Strategy

Early in life, Linnet saw firsthand how a clinical trial can radically extend and improve a cancer patient’s life. She became deeply interested in how targeted therapies can play a crucial role in optimizing treatment for oncology patients. Working in drug development, Linnet combines her desire to improve patients’ lives with her passion for turning data into actionable insights.
 
Linnet joined Revolution Medicines in March 2019 and has played a key leadership role in the evolution of the Finance department. She has over 15 years of finance, accounting, and commercial operations experience and has worked at oncology focused biotech companies for over 12 years. Prior to RevMed, Linnet worked at Aduro Biotech and Onyx Pharmaceuticals (now Amgen), holding various roles in both Finance and Commercial organizations, including supporting the launch and commercialization of KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab). She started her professional career in the life sciences practice at Ernst & Young.
 
Linnet received her bachelor’s degree from UCLA in Economics with an emphasis in Accounting and holds an active CPA license.